Reference
1. Organization WH. The molecular genetic epidemiology of Cystic
Fibrosis : report of a joint meeting of WHO/ECFTN/ICF(M)A/ECFS. Genoa,
Italy - 19 june 20022004.
2. Stephenson AL, Tom M, Berthiaume Y, Singer LG, Aaron SD, Whitmore GA,
et al. A contemporary survival analysis of individuals with cystic
fibrosis: a cohort study. Eur Respir J. 2015;45(3):670-9.
3. Mehta G, Macek M, Mehta A, Group ERW. Cystic fibrosis across Europe:
EuroCareCF analysis of demographic data from 35 countries. J Cyst
Fibros. 2010;9 Suppl 2:S5-S21.
4. Salvatore D, Buzzetti R, Mastella G. Update of literature from cystic
fibrosis registries 2012-2015. Part 6: Epidemiology, nutrition and
complications. Pediatr Pulmonol. 2017;52(3):390-8.
5. MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH,
et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and
beyond: survival analysis of the Cystic Fibrosis Foundation patient
registry. Ann Intern Med. 2014;161(4):233-41.
6. Lai HJ, Cheng Y, Cho H, Kosorok MR, Farrell PM. Association between
initial disease presentation, lung disease outcomes, and survival in
patients with cystic fibrosis. Am J Epidemiol. 2004;159(6):537-46.
7. Yen EH, Quinton H, Borowitz D. Better nutritional status in early
childhood is associated with improved clinical outcomes and survival in
patients with cystic fibrosis. J Pediatr. 2013;162(3):530-5.e1.
8. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas
aeruginosa and other predictors of mortality and morbidity in young
children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91-100.
9. Blanchard AC, Waters VJ. Microbiology of Cystic Fibrosis Airway
Disease. Semin Respir Crit Care Med. 2019;40(6):727-36.
10. O’Shea D, O’Connell J. Cystic fibrosis related diabetes. Curr Diab
Rep. 2014;14(8):511.
11. Chamnan P, Shine BS, Haworth CS, Bilton D, Adler AI. Diabetes as a
determinant of mortality in cystic fibrosis. Diabetes Care.
2010;33(2):311-6.
12. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic
fibrosis-related diabetes: current trends in prevalence, incidence, and
mortality. Diabetes Care. 2009;32(9):1626-31.
13. Barr HL, Britton J, Smyth AR, Fogarty AW. Association between
socioeconomic status, sex, and age at death from cystic fibrosis in
England and Wales (1959 to 2008): cross sectional study. BMJ.
2011;343:d4662.
14. Waters V, Ratjen F. Pulmonary Exacerbations in Children with Cystic
Fibrosis. Ann Am Thorac Soc. 2015;12 Suppl 2:S200-6.
15. Harness-Brumley CL, Elliott AC, Rosenbluth DB, Raghavan D, Jain R.
Gender differences in outcomes of patients with cystic fibrosis. J
Womens Health (Larchmt). 2014;23(12):1012-20.
16. H. L-R. Los niveles socioeconómicos en México y la distribución del
gasto. 2009.
17. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation
of a new definition for chronic Pseudomonas aeruginosa infection in
cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29-34.
18. Gómez Dantés O, Sesma S, Becerril VM, Knaul FM, Arreola H, Frenk J.
[The health system of Mexico]. Salud Publica Mex. 2011;53 Suppl
2:s220-32.
19. Keogh RH, Stanojevic S. A guide to interpreting estimated median age
of survival in cystic fibrosis patient registry reports. J Cyst Fibros.
2018;17(2):213-7.
20. Foundation CF. 2019 Cystic fibrosis Foundation Patient Registry
Highlights. 2019.
21. Kerem E, Cohen-Cymberknoh M. Disparities in Cystic Fibrosis Care and
Outcome: Socioeconomic Status and Beyond. Chest. 2016;149(2):298-300.
22. Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC. The
association of socioeconomic status with outcomes in cystic fibrosis
patients in the United States. Am J Respir Crit Care Med.
2001;163(6):1331-7.
23. Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener
JS, et al. Association of socioeconomic status with the use of chronic
therapies and healthcare utilization in children with cystic fibrosis. J
Pediatr. 2009;155(5):634-9.e1-4.
24. O’Connor GT, Quinton HB, Kneeland T, Kahn R, Lever T, Maddock J, et
al. Median household income and mortality rate in cystic fibrosis.
Pediatrics. 2003;111(4 Pt 1):e333-9.
25. Taylor-Robinson DC, Thielen K, Pressler T, Olesen HV, Diderichsen F,
Diggle PJ, et al. Low socioeconomic status is associated with worse lung
function in the Danish cystic fibrosis population. Eur Respir J.
2014;44(5):1363-6.
26. Watts KD, Seshadri R, Sullivan C, McColley SA. Increased prevalence
of risk factors for morbidity and mortality in the US Hispanic CF
population. Pediatr Pulmonol. 2009;44(6):594-601.
27. McGarry ME, Williams WA, McColley SA. The demographics of adverse
outcomes in cystic fibrosis. Pediatr Pulmonol. 2019;54 Suppl 3:S74-S83.
28. E BA. Early acquisition of Pseudomonas aeruginosa in Mexican
children with cystic fibrosis. Acta Pediatr Mex; 2020. p. 159-64.
29. Sathe M, Houwen R. Meconium ileus in Cystic Fibrosis. J Cyst Fibros.
2017;16 Suppl 2:S32-S9.
30. E Y. Correlación genotipo -fenotipo en una muestra de pacientes
mexicanos con fibrosis quística. Rev Invest Clin; 2013. p. 491-9.
31. Chávez-Saldaña M, Yokoyama E, Lezana JL, Carnevale A, Macías M,
Vigueras RM, et al. CFTR allelic heterogeneity in Mexican patients with
cystic fibrosis: implications for molecular screening. Rev Invest Clin.
2010;62(6):546-52.
32. Selvadurai HC, Blimkie CJ, Cooper PJ, Mellis CM, Van Asperen PP.
Gender differences in habitual activity in children with cystic
fibrosis. Arch Dis Child. 2004;89(10):928-33.
33. Zeitlin PL. Cystic fibrosis and estrogens: a perfect storm. J Clin
Invest. 2008;118(12):3841-4.
34. Fogarty AW, Britton J, Clayton A, Smyth AR. Are measures of body
habitus associated with mortality in cystic fibrosis? Chest.
2012;142(3):712-7.